Key Points
- Insider sale: EVP David Elkins sold 30,000 BMY shares on April 1 at an average price of $61.67 for $1.85M, cutting his stake by ~15.9% to 159,248 shares (worth ~ $9.82M).
- Earnings miss but guidance set: Bristol Myers Squibb reported Q EPS of $1.26 versus $1.65 expected (revenue $12.5B slightly ahead) and provided FY‑2026 guidance of $6.05–$6.35 per share (analysts forecast ~6.74).
- Dividend yield: The company declared a quarterly dividend of $0.63 ($2.52 annualized), reflecting a ~4.2% yield and a payout ratio of about 73%.
Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) EVP David Elkins sold 30,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Bristol Myers Squibb Stock Performance
Shares of BMY opened at $59.57 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm's fifty day simple moving average is $59.27 and its two-hundred day simple moving average is $52.57. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The stock has a market capitalization of $121.63 billion, a P/E ratio of 17.27, a price-to-earnings-growth ratio of 0.18 and a beta of 0.27.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the firm earned $1.67 earnings per share. The firm's revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb's payout ratio is presently 73.04%.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of BMY. Norges Bank purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at $1,947,272,000. AQR Capital Management LLC grew its stake in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock valued at $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares in the last quarter. Finally, Man Group plc boosted its holdings in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently issued reports on BMY. Scotiabank reissued a "sector perform" rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 target price on the stock. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research report on Tuesday, January 13th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus target price of $61.41.
Get Our Latest Analysis on BMY
More Bristol Myers Squibb News
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Positive Phase 3 data for Camzyos (SCOUT‑HCM) in adolescents may expand the label/profile for BMY’s cardiac myosin inhibitor, strengthening the late‑stage pipeline and future revenue potential. SCOUT‑HCM Trial Results
- Positive Sentiment: Janux Therapeutics triggered a $35M milestone under its collaboration with BMY after nominating a development candidate — a near‑term cash/partner validation and a de‑risking signal for partnered R&D. Janux Milestone
- Positive Sentiment: Unusually large call‑option activity (≈66,900 calls traded) indicates speculative bullish interest from traders positioning for upside. (Market data entry)
- Positive Sentiment: Analyst commentary and screens (Zacks/Trefis pieces) highlight BMY’s history of earnings surprises and a view that the company has ingredients to beat upcoming results — supportive for investor sentiment. Analyst Coverage
- Neutral Sentiment: Analyses project HNSCC market growth to ~$4.5B by 2034 (CAGR ≈8.4%), a long‑term addressable market note that may matter if BMY advances therapies in that space. HNSCC Market Outlook
- Neutral Sentiment: Reports on growth in the advanced renal cell carcinoma market highlight broader oncology tailwinds that include BMY among peers — useful context but not an immediate stock catalyst. RCC Market Report
- Neutral Sentiment: BMY published community and program updates around multiple myeloma care and equity initiatives — positive for ESG/community positioning but unlikely to move near‑term revenue. Community Program Release
- Negative Sentiment: Insider selling: EVP David V. Elkins sold 30,000 shares at ~$61.67 on April 1 (Form 4 filing), reducing his stake ~15.9% — an action investors may view negatively even if it’s routine. Insider Form 4
- Negative Sentiment: Recent quarterly results (reported Feb. 5) showed an EPS miss ($1.26 vs. $1.65 est.), even as revenue slightly beat; that earnings disappointment and investor focus on near‑term profitability remain headwinds despite FY‑26 guidance of $6.05–$6.35. (Company filings/earnings release)
About Bristol Myers Squibb
(
Get Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
